Ocular Therapeutix (OCUL) EBITDA (2013 - 2026)
Ocular Therapeutix's quarterly EBITDA came in at -$93.3 million in Q1 2026, down 46.03% year-on-year from -$173.0 million in Q1 2025, and down 33.8% quarter-over-quarter from -$69.8 million in Q4 2025.
Ocular Therapeutix has reported EBITDA for 14 years, with the latest figure at -$93.3 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 46.03% year-over-year to -$93.3 million; the trailing twelve-month figure through Mar 2026 stood at -$299.4 million (down 46.73% YoY), and the FY2025 full-year result was -$270.0 million, down 57.19% from the prior year.
- EBITDA for Q1 2026 stood at -$93.3 million, down from -$69.8 million in the prior quarter.
- The five-year high for EBITDA was -$17.8 million in Q1 2022, with the low at -$93.3 million in Q1 2026.
- Average EBITDA over 5 years is -$41.0 million, with a median of -$31.6 million recorded in 2024.
- Year-over-year, EBITDA rose 11.84% in 2022 and slumped 152.25% in 2024.
- Tracing OCUL's EBITDA over 5 years: stood at -$19.4 million in 2022, then dropped by 3.56% to -$20.0 million in 2023, then tumbled by 152.25% to -$50.6 million in 2024, then tumbled by 37.93% to -$69.8 million in 2025, then slumped by 33.8% to -$93.3 million in 2026.
- The last three EBITDA figures came in at -$93.3 million (Q1 2026), -$69.8 million (Q4 2025), and -$68.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -93.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.34 Mn |
| Dec 31, 2025 | -69.76 Mn |
| Sep 30, 2025 | -68.70 Mn |
| Jun 30, 2025 | -67.64 Mn |
| Mar 31, 2025 | -63.92 Mn |
| Dec 31, 2024 | -50.58 Mn |
| Sep 30, 2024 | -46.00 Mn |
| Jun 30, 2024 | -43.59 Mn |
| Mar 31, 2024 | -31.62 Mn |
| Dec 31, 2023 | -20.05 Mn |
| Sep 30, 2023 | -19.21 Mn |
| Jun 30, 2023 | -20.57 Mn |
| Mar 31, 2023 | -22.55 Mn |
| Dec 31, 2022 | -19.36 Mn |
| Sep 30, 2022 | -21.54 Mn |
| Jun 30, 2022 | -19.92 Mn |
| Mar 31, 2022 | -17.83 Mn |
| Dec 31, 2021 | -18.05 Mn |
| Sep 30, 2021 | -19.53 Mn |
| Jun 30, 2021 | -20.23 Mn |
| Mar 31, 2021 | -20.23 Mn |
| Dec 31, 2020 | -14.34 Mn |
| Sep 30, 2020 | -14.01 Mn |
| Jun 30, 2020 | -17.88 Mn |
| Mar 31, 2020 | -16.61 Mn |
| Dec 31, 2019 | -21.40 Mn |
| Sep 30, 2019 | -23.14 Mn |
| Jun 30, 2019 | -21.60 Mn |
| Mar 31, 2019 | -19.66 Mn |
| Dec 31, 2018 | -17.40 Mn |
| Sep 30, 2018 | -15.01 Mn |
| Jun 30, 2018 | -13.80 Mn |
| Mar 31, 2018 | -13.77 Mn |
| Dec 31, 2017 | -13.10 Mn |
| Sep 30, 2017 | -15.57 Mn |
| Jun 30, 2017 | -18.69 Mn |
| Mar 31, 2017 | -16.03 Mn |
| Dec 31, 2016 | -12.83 Mn |
| Sep 30, 2016 | -9.60 Mn |
| Jun 30, 2016 | -11.44 Mn |
| Mar 31, 2016 | -10.77 Mn |
| Dec 31, 2015 | -10.69 Mn |
| Sep 30, 2015 | -11.53 Mn |
| Jun 30, 2015 | -10.02 Mn |
| Mar 31, 2015 | -7.58 Mn |
| Dec 31, 2014 | -7.95 Mn |
| Sep 30, 2014 | -7.29 Mn |
| Jun 30, 2014 | -6.39 Mn |
| Mar 31, 2014 | -6.83 Mn |
| Dec 31, 2013 | -3.42 Mn |
| Sep 30, 2013 | -3.44 Mn |
| Jun 30, 2013 | -2.99 Mn |